Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.37 |
| ▸ | PDE4A | P27815 | 9/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 8/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TTK | P33981 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2430197 | 0.91 | PDE4A (0.40) | PDE4BPDE4DPDE4APDE4CIDO1 | |
| SCHEMBL2432859 | 0.87 | ADORA3 (0.43) | ADORA3IDO1 | |
| SCHEMBL2433379 | 0.86 | PDE4D (0.38) | PDE4BPDE4DPDE4APDE4CIDO1 | |
| SCHEMBL1136283 | 0.85 | KDR (0.38) | PDE4BPDE4DPDE4APDE4CIDO1 | |
| SCHEMBL1136272 | 0.85 | IDO1 (0.37) | PDE4BPDE4DPDE4APDE4CIDO1 | |
| SCHEMBL2430280 | 0.84 | ADORA3 (0.42) | ADORA3IDO1 | |
| SCHEMBL15198840 | 0.79 | TSHR (0.39) | PDE4BPDE4DPDE4APDE4CPDE3A | |
| SCHEMBL1136007 | 0.78 | ADORA3 (0.40) | ADORA3IDO1 | |
| SCHEMBL2523334 | 0.77 | PDE4A (0.41) | PDE4BPDE4DPDE4APDE4CIDO1 | |
| SCHEMBL2430302 | 0.76 | ALDH1A1 (0.46) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010064701-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | 大塚製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | PDE4B 272/4885PDE4D 542/4885PDE4A 301/4885 |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | PDE4B 272/4885PDE4D 542/4885PDE4A 301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.